1Overview: Two Metabolites, Divergent Paths
At a Glance
Urolithin A and Urolithin B are both dibenzopyran-6-one metabolites produced by the human gut microbiome from dietary ellagitannins (found in pomegranates, berries, walnuts, and chestnuts). Despite sharing a common precursor — ellagic acid — and a nearly identical benzocoumarin scaffold, these two postbiotic molecules diverge dramatically in their hydroxylation pattern, primary mechanism of action, clinical research depth, and target-tissue distribution.
Urolithin A is a potent mitophagy inducer with multiple published human clinical trials demonstrating improvements in muscle strength, endurance, and mitochondrial function. Urolithin B is a broad-spectrum anti-inflammatory and antioxidant agent with strong preclinical data for cardiovascular, renal, and neuroprotective applications — though it currently lacks the depth of human clinical evidence that Urolithin A commands.
Understanding the structural, metabolic, mechanistic, and translational differences between these two urolithins is essential for researchers designing studies in aging, metabolic disease, neurodegeneration, or cardiovascular research.
2Chemical Structure: One Hydroxyl Group Changes Everything
The single most consequential difference between Urolithin A and Urolithin B lies in their hydroxylation pattern. This difference — one extra hydroxyl group — cascades into profound effects on target affinity, metabolic stability, tissue distribution, and biological activity.
🔬 Urolithin A Dihydroxy
3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one
Two hydroxyl groups at positions 3 and 8 on the benzocoumarin scaffold
🔬 Urolithin B Monohydroxy
3-hydroxy-6H-dibenzo[b,d]pyran-6-one
Single hydroxyl group at position 3 only — position 8 is unsubstituted
The presence of the second hydroxyl group at position 8 in Urolithin A enhances its hydrogen-bonding capacity, which directly affects its interaction with PINK1/Parkin pathway proteins involved in mitophagy initiation. Urolithin B's simpler structure — lacking this extra polar moiety — makes it more lipophilic, which contributes to its preferential accumulation in lipid-rich tissues such as the myocardium and brain. This structural divergence is the root cause of nearly every other difference between the two compounds.
Key Insight: In the ellagitannin metabolic cascade, Urolithin A (a dihydroxy-urolithin) is an upstream intermediate, while Urolithin B (a monohydroxy-urolithin) is formed downstream through further dehydroxylation. Only individuals with the complete set of dehydroxylating gut bacteria can produce Urolithin B — a fact that underpins the concept of urolithin metabotypes.
3Metabolic Origin: The Gut Microbiome Gatekeeper
Neither Urolithin A nor Urolithin B exists naturally in food. Both are postbiotic metabolites — biologically active compounds produced exclusively by gut microbiota acting on dietary polyphenols. The production pathway proceeds through a multi-step microbial transformation:
- Step 1 — Hydrolysis: Dietary ellagitannins (from pomegranates, raspberries, walnuts, etc.) are hydrolyzed in the gastrointestinal tract to release ellagic acid (EA).
- Step 2 — Lactone ring opening: Gut bacteria open the lactone ring of EA to form pentahydroxy-urolithin (Urolithin M5).
- Step 3 — Sequential dehydroxylation: Successive removal of hydroxyl groups yields tetrahydroxy-, trihydroxy-, and finally dihydroxy-urolithins including Urolithin A.
- Step 4 — Final dehydroxylation: In individuals harboring the complete suite of urolithin-producing bacteria, further dehydroxylation converts Urolithin A into Urolithin B (monohydroxy).
3.1 Urolithin Metabotypes: Not Everyone Produces the Same Metabolites
Population studies have identified three distinct urolithin metabotypes based on an individual's gut microbiome composition:
| Metabotype | Urolithins Produced | Population Prevalence | Implication |
|---|---|---|---|
| UM-A | Urolithin A only | ~30–60% (varies by region) | Can produce UA but not UB; lacks final dehydroxylation step |
| UM-B | Urolithin A + Urolithin B + Isourolithin A | ~10–30% | Full urolithin-producing capability; richest metabolite profile |
| UM-0 | None (or undetectable) | ~10–60% (regional variation) | Cannot convert EA to urolithins; may benefit most from direct supplementation |
The practical consequence of metabotype variation is critical for research: UM-A individuals cannot produce Urolithin B endogenously, and UM-0 individuals cannot produce either compound. Direct dietary supplement administration bypasses this gut-microbiome lottery entirely, ensuring reproducible systemic exposure regardless of metabotype — a rationale that has driven commercial development of both compounds as standalone research ingredients.
4Mechanism of Action: Mitophagy vs Multi-Pathway Defense
While both urolithins are frequently grouped under the umbrella term "ellagitannin metabolites with health benefits," their primary mechanisms of action are fundamentally different.
Urolithin A Mitophagy & Mitochondrial Renewal
Primary mechanism: Induces mitophagy — the selective autophagic clearance of damaged mitochondria — via PINK1/Parkin pathway activation. This triggers mitochondrial quality control, removing dysfunctional organelles and stimulating mitochondrial biogenesis.
Secondary effects: Activates SIRT1, inhibits mTOR, activates AMPK, upregulates Nrf2-mediated antioxidant defenses, and crosses the blood–brain barrier.
Hallmark: UA is often described as a "mitochondrial fitness molecule." Its effects on muscle endurance, cellular senescence, and neuroprotection are all downstream of restored mitochondrial homeostasis.
Urolithin B Anti-Inflammatory & Antioxidant Defense
Primary mechanism: Broad-spectrum anti-inflammatory action through inhibition of NF-κB signaling, suppression of TLR4-mediated inflammatory cascades, and reduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β).
Secondary effects: Direct free-radical scavenging, upregulation of endogenous antioxidant enzymes (SOD, CAT, GPx), modulation of PI3K/Akt and MAPK pathways, and regulation of lipid metabolism through PPAR-α.
Hallmark: UB's effects are concentrated in tissues subject to oxidative and inflammatory stress — the heart, kidneys, pancreas, and vascular endothelium.
4.1 Complementary, Not Interchangeable
It would be a mistake to treat Urolithin A and Urolithin B as substitutes. Their mechanisms are orthogonal but complementary — UA renews mitochondrial infrastructure (quality control), while UB defends against inflammatory and oxidative damage (environmental protection). In contexts where both mitochondrial dysfunction and chronic inflammation coexist — aging, metabolic syndrome, neurodegeneration — these mechanisms may be additive or synergistic, though formal combination studies remain limited.
5Efficacy Comparison: Where the Data Stands
5.1 Urolithin A — Clinically Validated
- Muscle function: Multiple randomized controlled trials (RCTs) have demonstrated that UA supplementation (500–1000 mg/day) improves lower-limb muscle strength by approximately 12%, enhances aerobic endurance, and increases mitochondrial gene expression in skeletal muscle of middle-aged and older adults. A 2024 study extended these findings to strength-trained young athletes.
- Mitochondrial health: UA activates mitophagy markers and improves mitochondrial respiratory capacity in human subjects. Preclinical data confirm PINK1/Parkin pathway engagement, with dose-dependent mitochondrial turnover.
- Cellular senescence: UA reduces markers of cellular senescence, including p21 and p16 expression, via mitophagy-dependent clearance of senescent mitochondria.
- Neuroprotection: Animal models of Alzheimer's disease show reduced amyloid-β deposition, tau hyperphosphorylation, and neuroinflammation following UA administration. UA crosses the blood–brain barrier, making CNS applications mechanistically plausible.
- Skin aging: A 2023 clinical study found that topical UA (1% cream) significantly reduced facial wrinkle depth, improved skin hydration, and suppressed collagen degradation.
- Metabolic health: UA improves insulin sensitivity and reduces body weight gain in diet-induced obese mouse models. NAFLD/NASH preclinical data are emerging.
- Immune rejuvenation: A 2023 Nature study reported that UA restored aged hematopoietic stem cell function to youthful levels in mice, reversing age-related immune decline.
- GRAS status: FDA has granted Generally Recognized as Safe (GRAS) designation for UA. Safety studies at doses up to 1000 mg/day for 28 days reported no adverse effects.
5.2 Urolithin B — Preclinically Promising
- Cardiovascular protection: UB protects against cardiac dysfunction in streptozotocin-induced diabetic rat models. In vitro studies demonstrate improved cholesterol efflux from macrophage foam cells, suggesting anti-atherosclerotic potential. Notably, UB accumulates preferentially in cardiac tissue following administration.
- Nephroprotection: UB attenuates cisplatin-induced nephrotoxicity and ischemia-reperfusion kidney injury in rodent models via anti-inflammatory and anti-oxidative mechanisms.
- Neuroprotection: Preclinical models suggest UB protects against neuroinflammation and oxidative neuronal injury, though the mechanistic data are less developed than for UA's CNS effects.
- Anti-diabetic effects: UB improves glycemic control and lipid profiles in rodent models of diabetes. It reduces serum cholesterol, triglycerides, and body weight in HFD-fed mice.
- Anti-tumor potential: UB inhibits proliferation and induces apoptosis in various cancer cell lines (colorectal, breast, gastric), though studies are limited to in vitro systems.
- Anti-obesity: Both UA and UB reduce fat mass in HFD-fed mice, but UB's effect appears to operate through anti-inflammatory rather than mitophagy pathways.
6Bioavailability & Tissue Distribution
Both urolithins undergo extensive phase-II metabolism (glucuronidation, sulfation, and methylation) in enterocytes and the liver. However, their pharmacokinetic profiles differ meaningfully.
6.1 Systemic Exposure
6.2 Tissue Distribution Patterns
| Tissue / Organ | Urolithin A Detected | Urolithin B Detected |
|---|---|---|
| Small intestine / Colon | ✓ (high concentrations) | ✓ |
| Liver | ✓ | ✓ |
| Kidney | ✓ | ✓ |
| Prostate | ✓ | Not reported |
| Skeletal muscle | ✓ | Not reported |
| Brain (crosses BBB) | ✓ | Limited data |
| Heart (myocardium) | ✓ | ✓ (preferential accumulation) |
| Pancreas | ✓ | ✓ |
| Breast tissue | ✓ | Not reported |
| Lung | ✓ | Not reported |
Source: Human tissue studies (prostate, colon, breast, muscle); rat tissue distribution studies (remaining organs).
Research Implication: The preferential cardiac accumulation of Urolithin B — combined with its anti-inflammatory profile — makes it a particularly compelling candidate for cardiovascular disease research. Conversely, Urolithin A's detection in skeletal muscle, brain, and skin aligns with its clinical validation in muscle function, neuroprotection, and dermatological applications.
7Clinical Research Gap: Man vs Mouse
The single largest differentiator between Urolithin A and Urolithin B in 2026 is the stark asymmetry in human clinical evidence.
| Evidence Category | Urolithin A | Urolithin B |
|---|---|---|
| Published human RCTs | 5+ (Amazentis/Mitopure program) | None |
| Registered clinical trials | Active (multiple sites) | None registered |
| FDA regulatory status | GRAS (Generally Recognized as Safe) | Not reviewed |
| Safety data in humans | 28-day studies; no SAEs up to 1000 mg/day | Limited to preclinical |
| Human PK data | Published (Tmax, t½, metabolites) | Very limited |
| Systematic review / meta-analysis | 2024 review published | None |
| Commercial supplement market | Multiple brands (Mitopure, Timeline) | Emerging |
This clinical evidence asymmetry reflects commercial development history rather than intrinsic scientific merit — Urolithin B's preclinical data are strong, but the translational leap to human trials has not yet been made. Researchers investigating UB should treat this as both a caution and an opportunity: UB's preclinical promise across cardiovascular, renal, and metabolic domains awaits human validation.
8Target Population & Research Fit
Selecting between Urolithin A and Urolithin B for a research program should be guided by the target biology, not by brand recognition.
Choose Urolithin A When Your Research Focuses On:
- Mitochondrial dysfunction, sarcopenia, or age-related muscle decline
- Cellular senescence and aging biology
- Neurodegenerative disease (Alzheimer's, Parkinson's preclinical models)
- Exercise physiology and muscle performance
- Skin aging and dermatological research
- Hematopoietic stem cell aging and immune rejuvenation
- Any study requiring human-validated dosing and safety data
Choose Urolithin B When Your Research Focuses On:
- Cardiovascular disease models (atherosclerosis, diabetic cardiomyopathy, heart failure)
- Renal injury and nephroprotection
- Chronic inflammatory conditions (IBD, arthritis)
- Oxidative stress-driven pathologies
- Diabetes and metabolic syndrome (lipid metabolism, glycemic control)
- Oncology research (cell proliferation, apoptosis in cancer lines)
- Any study where tissue-specific anti-inflammatory action is the primary endpoint
⚠️ Important: For research programs targeting mechanisms that involve both mitochondrial dysfunction and chronic inflammation — such as metabolic syndrome, NAFLD, or neurodegeneration — a combination study design may be scientifically justified. However, no published combination data exist as of July 2026, and researchers should design such studies with full dose-response characterization for each compound independently before combining.
9Head-to-Head Comparison Table
The following table is the definitive reference for comparing Urolithin A and Urolithin B across all major dimensions. This section carries the highest information density in this article — bookmark it for quick reference.
| Parameter | Urolithin A ✅ | Urolithin B 🔵 |
|---|---|---|
| Common Name | Urolithin A (UA) | Urolithin B (UB) |
| IUPAC Name | 3,8-Dihydroxy-6H-dibenzo[b,d]pyran-6-one | 3-Hydroxy-6H-dibenzo[b,d]pyran-6-one |
| CAS Number | 1143-70-0 | 1139-83-9 |
| Molecular Formula | C₁₃H₈O₄ | C₁₃H₈O₃ |
| Molecular Weight | 228.20 g/mol | 212.20 g/mol |
| Hydroxyl Groups | 2 (positions 3 and 8) — dihydroxy | 1 (position 3) — monohydroxy |
| Metabolic Position | Upstream intermediate (dihydroxy-urolithin) | Downstream end-product (monohydroxy-urolithin) |
| Primary Mechanism | Mitophagy induction (PINK1/Parkin pathway) | Anti-inflammatory (NF-κB, TLR4 inhibition) |
| Secondary Mechanisms | SIRT1 ↑, AMPK ↑, mTOR ↓, Nrf2 ↑ | PI3K/Akt, MAPK modulation, PPAR-α ↑ |
| Antioxidant Activity | Moderate (Nrf2-mediated) | Strong (direct radical scavenging + enzyme upregulation) |
| Human Clinical Trials | Yes — 5+ RCTs published | None published as of July 2026 |
| FDA Regulatory Status | GRAS (Generally Recognized as Safe) | Not reviewed / not established |
| Human Safety Data | 28-day studies, up to 1000 mg/day, no SAEs | Limited to preclinical toxicology |
| Human PK Published | Yes — Tmax 6h, t½ 17–58h | Very limited human data |
| Primary Distribution | Muscle, brain, skin, colon, prostate, liver | Heart (preferential), pancreas, liver, kidneys |
| Crosses BBB | ✓ Confirmed | Limited evidence |
| Phase-II Conjugates | Glucuronide, sulfate, methyl | Glucuronide, sulfate |
| Endogenous Production | UM-A and UM-B metabotypes | UM-B metabotype only |
| Dietary Sources | None directly — gut metabolite from ET/EA | None directly — gut metabolite from ET/EA |
| Best Research Fit | Aging, muscle, mitochondria, neurodegeneration, skin | Cardiovascular, renal, inflammation, diabetes |
| Commercial Availability | Multiple suppliers, branded (Mitopure®) and generic | Emerging; fewer suppliers, no major brand |
| Evidence Maturity | Phase II clinical / commercial supplement | Preclinical / early translational |
10Common Misconceptions
Reality: They target fundamentally different pathways. UB's anti-inflammatory and cardiovascular effects are not a weaker version of UA's mitophagy effects — they are a different mechanism entirely. Comparing them on "effectiveness" without specifying the biological endpoint is scientifically meaningless.
Reality: Urolithin production from dietary ellagitannins depends on gut microbiome composition. UM-0 individuals (10–60% of the population, depending on region) cannot produce any urolithins. Even UM-A individuals cannot produce Urolithin B. Furthermore, one study showed that 500 mg of direct UA supplementation produced significantly higher plasma UA levels than 240 mL of pomegranate juice rich in natural precursors. Direct supplementation eliminates metabotype variability.
Reality: Their tissue distribution, primary mechanism, and clinical evidence base are vastly different. Using UB as a substitute for UA in a mitophagy study (or vice versa) would produce invalid results. Researchers must match the compound to the biological question.
Reality: Absence of evidence is not evidence of absence. UB has been consumed by humans for millennia as a natural gut metabolite of ellagitannin-rich foods (in UM-B metabotype individuals). The lack of formal human clinical trials reflects commercial investment priorities, not an identified safety signal. Preclinical toxicology data are reassuring, but formal human safety studies are needed.
Reality: Direct oral supplementation of purified Urolithin A or Urolithin B bypasses gut microbial conversion entirely. The 2021 European Journal of Clinical Nutrition study demonstrated that direct UA supplementation produces uniform circulating UA levels across all metabotypes. Supplementation is the great equalizer.
11Frequently Asked Questions
Q: What is the single most important difference between Urolithin A and Urolithin B?
The number and position of hydroxyl groups on the benzocoumarin scaffold. Urolithin A has two OH groups (positions 3 and 8); Urolithin B has one (position 3 only). This structural difference drives their divergent mechanisms (mitophagy vs anti-inflammatory), tissue distributions, and clinical development trajectories.
Q: Which urolithin has more human clinical data?
Urolithin A — by a large margin. As of July 2026, UA has been studied in multiple published randomized controlled trials involving healthy adults across several countries, with consistent findings of improved muscle function and mitochondrial health. Urolithin B has zero published human RCTs.
Q: Can I take Urolithin A and Urolithin B together?
From a mechanistic standpoint, they target complementary pathways and are not antagonistic. However, no published combination studies exist, and researchers should conduct full dose-response characterization for each compound independently before designing combination protocols. The safety of combined administration has not been formally evaluated.
Q: Why do some people produce Urolithin B naturally and others don't?
Urolithin B production requires the complete suite of dehydroxylating gut bacteria (including Gordonibacter and Enterocloster species). Only approximately 10–30% of the population — classified as UM-B metabotype — harbors the full bacterial consortium needed for the final dehydroxylation step that converts UA to UB. Factors including age, diet, antibiotic history, and geography influence metabotype distribution.
Q: Which compound is better for cardiovascular research?
Urolithin B has the stronger preclinical cardiovascular evidence base: it accumulates preferentially in heart tissue, improves cardiac function in diabetic rodent models, and enhances cholesterol efflux from macrophage foam cells. However, this data is entirely preclinical. Urolithin A's cardiovascular benefits are inferred from its effects on mitochondrial function and inflammation reduction, but cardiovascular disease is not UA's primary research domain.
Q: Does Urolithin B cross the blood–brain barrier?
Evidence is limited. Urolithin A has been confirmed to cross the BBB in animal models, but equivalent data for Urolithin B are sparse. Given UB's more lipophilic character, penetration is theoretically possible, but direct confirmation is lacking. Researchers designing CNS studies should account for this uncertainty.
Q: What regulatory status do these compounds hold?
Urolithin A has achieved FDA GRAS (Generally Recognized as Safe) status and is commercially available as a dietary supplement ingredient. Urolithin B has not been formally reviewed by the FDA and does not hold an independent GRAS designation. Neither compound is an FDA-approved drug. All studies should comply with applicable institutional and national regulations.
Q: How do I know my urolithin metabotype?
Metabotype determination requires specialized analysis of urinary or plasma urolithin metabolites following consumption of ellagitannin-rich foods or a standardized precursor dose. A few commercial testing services offer metabotype profiling, but these are not widely available. For research purposes, metabotype can be inferred from controlled precursor-feeding studies with metabolite quantification by LC-MS/MS.
Source High-Purity Urolithins for Your Research
We supply both Urolithin A (CAS 1143-70-0) and Urolithin B (CAS 1139-83-9) as analytically verified research powders. Full COA documentation, competitive institutional pricing, and global fulfillment available.